Many patients are unaware they might have keratoconus and they see their eye doctor because of increasing spectacle blur or progressive changes in their prescription. In many instances even a good refraction yields poor vision. Keratoconus should be diagnosed by a cornea specialist who may see typical findings when examining the patient at the slit-lamp.
In early forms of the disease there may be no obvious finding on slit-lamp evaluation and the diagnosis is made by computerized video keratography only. Keratoconus can start at puberty and progresses to the mid thirties at which time progression slows and often stops. Because it affects the young primarily, Keratoconus is a serious eye disease.
Keratoconus treatment here in Los Angeles depends on your symptoms. When your symptoms are mild, your vision can be corrected with eyeglasses. Later you may need to wear special hard contact lenses to help keep vision in proper focus. However, a permanent treatment to Keratoconus does exist.
New research suggests the weakening of the corneal tissue that leads to keratoconus may be due to an imbalance of enzymes within the cornea. This imbalance makes the cornea more susceptible to oxidative damage from compounds called free radicals, causing it to weaken and bulge forward.
A number of surgical options are available to the keratoconus patient. Since keratoconus can vary widely from patient to patient, the proper recommendation of any of these procedures depends on the individual nature of your problem.
Now, doctors can perform multiple types of corneal transplants, including deep anterior lamellar keratoplasty (DALK). DALK has emerged as the preferred transplant approach for keratoconus in most countries, although penetrating keratoplasty (PK) remains more popular in the United States.
One of the perceived advantages of DALK is that there is no risk of endothelial rejection, which should result in a higher likelihood of long-term allograft survival.
Dr. Khanna and the Keratoconus experts at Khanna Vision Institute are leading edge Los Angeles experts in the latest treatment options for Keratoconus. Dr. Khanna offers both DALK, Intacs for Keratoconus, and Cornea Cross Linking Riboflavin. Together, these leading treatments can help stop the progression of Keratoconus. Contact Dr. Khanna to get the latest technologies available for Keratoconus.
Crosslinking FDA approved. We are happy to announce that USA is now on par with the world. FDA after careful consideration has said cross linking is safe for treatment of Keratoconus.Avedro based in Massachusetts is the company, worked hard to get cross linking of cornea approved.
Cross Linking for treatment of Keratoconus has thus far been done only in FDA studies or off label in the US. Therefore it had been expensive. The protocols were often restrictive.Many doctors were hesitant to prescribe it for their patients.FDA approval will allow many more patients to seek treatment for their bulging corneas. In many patients it may be curative.
Keratoconus is a disease where the front clear part termed cornea is weak. It bends under outward pressure from the fluids inside the eye. This disease is rampant in the teenage years. It is often missed. Optometrists do not perform this exam as part of annual exam. Advanced diagnostic technologies like OCT tachometry map and color cornea topography help to detect it. Intervention in teenage years can save sight. All school going children should have this simple test performed and analyzed by a Corneal Keratoconus specialist.
Cross linking works by increasing the strength of the cornea. A strong cornea is able to tolerate the forces from within the eye. This prevents the further bulging of the eye. When cross linking is performed in the teenage years it decreases the progression of the disease. The positive effect can last over a decade. By than the normal progression of the disease is naturally slowed down.
Lear more about Management of Keratoconus eye disease by downloading the Keratoconus app. This app has been developed for non medical people to figure out what is best for them. Please click on the icon below
FDA approval will also allow insurances to cover the treatment. This will make the intervention by CXL affordable for people. A cat code code will soon be available. Financing options are also available.
For protocol of Cross-linking as approved by FDA